The future of weight loss is fast approaching. At a recent scientific conference, drug companies showed off a variety of next-generation drugs for both obesity and type 2 diabetes. Some of these treatments might help people lose even more weight than current forerunners like Novo Nordisk’s semaglutide—the active…
Children and teens with high body mass index should be guided toward intensive lifestyle interventions to manage their weight, an influential panel of experts is recommending.
It’s hard to go a day without hearing something new about the latest diabetes and obesity medications, semaglutide and tirzepatide. Usually, the buzz is positive, but there has been a persistent claim made about these drugs that would make any potential user wary: They don’t only help you lose weight—they supposedly…
Results from the longest-running trial of semaglutide—the active ingredient in the popular drugs Ozempic and Wegovy—are in, and the verdict is decidedly positive. The study found that people taking semaglutide tended to maintain their initial weight loss for up to four years. Other trial data presented this week also…
A popular class of weight loss drugs may offer more lasting success than assumed, new data from Epic Research suggests. The study of medical records found that a slight majority of people who took GLP-1 drugs like semaglutide either maintained or improved their weight loss in the year after they stopped using the…
Few prescription drugs have entered the public consciousness as abruptly as Ozempic and Wegovy have in recent years. Novo Nordisk’s brand-name medications have become as synonymous with weight loss as Viagra and Cialis are with erectile dysfunction. But while 2023 has made it clear that these and similar drugs really…
New research shows that tirzepatide, the latest FDA-approved obesity drug, really can help people lose substantial amounts of weight—but only if they continue taking it. The study found that people who stopped taking tirzepatide after 36 weeks regained much of their lost weight within a year, while those who continued…
There’s officially a new and fierce competitor for Novo Nordisk’s Wegovy (semaglutide) when it comes to weight loss. On Wednesday, the Food and Drug Administration approved the drug tirzepatide, developed by Eli Lilly, as a treatment for obesity. The weekly injectable drug will be sold under the brand name Zepbound.
New research suggests that Eli Lilly’s tirzepatide can boost existing efforts to lose weight. The company’s latest clinical trial found that people who dropped at least 5% of their weight before taking the drug went on to lose substantially more weight than those who took a placebo. Those in the treatment group…
Yulia Grigoryeva/Shutterstock
